SecBot SecBot
8-K ·Filed Feb 25, 2026

ALKS

Alkermes plc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago SEC0001193125-26-068927
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor leadership transition execution and Jackson's strategic direction, particularly regarding the integration of Avadel and development of the orexin agonist pipeline. No immediate financial impact expected, but long-term execution risk during transition should be assessed.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.03
T+0 close · Feb 25, 2026 · via day close
Latest settled
+19.19%
T+60 · $36.98
Vs SPY
+12.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $31.03entry
  2. T+1 · 9mo ago −0.90%α −0.36% · $30.75
  3. T+5 · 9mo ago −6.03%α −4.93% · $29.16
  4. T+20 · 8mo ago −5.41%α −0.18% · $29.35
  5. T+60 · 6mo ago +19.19%α +12.24% · $36.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alkermes plc announced the retirement of CEO and Chairman Richard F. Pops, effective July 31, 2026, after 35 years of service. He will be succeeded by current COO Blair C. Jackson, effective August 1, 2026. Pops will remain as non-executive Chairman and Senior Advisor through December 31, 2026, receiving a $75,000 monthly retainer, pro-rated bonus, and a $2.69 million equity award. The transition reflects a planned succession.

Key Facts

  • Richard F. Pops retires as CEO effective July 31, 2026, after 35 years; remains non-executive Chairman and Senior Advisor through December 31, 2026
  • Blair C. Jackson, current COO, appointed CEO effective August 1, 2026
  • Pops to receive $75,000 monthly retainer as Senior Advisor, pro-rated 2026 bonus, and $2,687,500 restricted stock unit award
  • Pops' equity awards will continue vesting during advisory period, with post-service vesting provisions for up to 21 months
  • Company highlighted strong commercial business, $1.5 billion in annual revenues, and late-stage pipeline including alixorexton for narcolepsy
  • Recent acquisition of Avadel Pharmaceuticals enhances sleep medicine commercial capabilities

Financial Impact

Approximately $2.69 million in equity compensation and $450,000 in cash ($75,000/month for 6 months) for Pops' advisory role, plus pro-rated bonus and board retainer

compensation expenseshare countnon-executive director fees

Risk Factors

  • Execution risk during CEO transition despite planned succession
  • Potential for strategic shift under new leadership affecting R&D priorities
  • Market perception of founder departure despite smooth transition plans

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-068927
Document: alks-ex99_1.htm0001193125-26-068927
Document: 0001193125-26-068927-index-headers.html0001193125-26-068927
Document: 0001193125-26-068927-index.html0001193125-26-068927
Document: 0001193125-26-068927.txt0001193125-26-068927

Track record

23 reports on ALKS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
  3. Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
  4. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
  5. Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
  6. Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
  7. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
  8. Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
  9. Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
  10. Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (10h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026